When in 2012, cyclist Lance Armstrong finally confessed to the most "sophisticated, professionalised and successful" doping programme the world had ever seen, he became sport's ultimate bogeyman.
His admission that for years he took a suite of supposedly performance-enhancing drugs, most prominently erythropoietin (EPO), saw him stripped of his seven Tour de France titles; his career and reputation in tatters.
So it may be with a certain queasiness that he learns today about the results of ground-breaking new research which suggests his prolonged campaign of abuse was pointless -- because EPO confers no advantage at all.
In the first study of its kind, scientists challenged a group of 48 cyclists to tackle a series of challenges, including the Mont Ventoux ascent, which often forms part of the Tour. Half had been given eight weekly injections of EPO, a drug that promotes red blood cell production with the aim of increasing delivery of oxygen to the muscles, while the other half took a dummy.
But after the gruelling 21.5km climb -- which was preceded by a 110km cycle for good measure -- the average results of the two groups showed no difference whatsoever.